ArticleJournal of neural transmission (Vienna, Austria : 1996)2013
Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Pooled it
- Response inhibition and emotional cognition improved by atomoxetine in children and adolescents with ADHD: The ACTION randomized controlled trial.Journal of psychiatric research · 2018Trial
- Variants of Dopamine Beta Hydroxylase Gene Moderate Atomoxetine Response in Children with Attention-Deficit/Hyperactivity Disorder.Journal of child and adolescent psychopharmacology · 2015Trial
- Inverse Association of Locus Coeruleus MRI Integrity With Structural Volume and Its Impact on Individual's Inattentiveness.Human brain mapping · 2025Article
- Selective Visual Attention in ADHD: A Narrative Review.Current neurology and neuroscience reports · 2025Review
- Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.European journal of clinical pharmacology · 2024Article
- Genetic Variants Linked to Dyslexia Co-Morbid ADHD: A Case Study of a Pakistani Outpatient.Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique · 2024Article
- Precision pharmacotherapy of atomoxetine in children with ADHD: how to ensure the right dose for the right person?Frontiers in pharmacology · 2024Review
- Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence.European journal of clinical pharmacology · 2023Review
- Influence of Receptor Polymorphisms on the Response to α-Adrenergic Receptor Blockers in Pheochromocytoma Patients.Biomedicines · 2022Article
- Genetics in the ADHD Clinic: How Can Genetic Testing Support the Current Clinical Practice?Frontiers in psychology · 2022Review
- CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders.Pharmacogenomics and personalized medicine · 2022Article
- Article
- Review
- Ethylphenidate as a selective dopaminergic agonist and methylphenidate-ethanol transesterification biomarker.Journal of pharmaceutical sciences · 2014Review
- Biomarkers in the diagnosis of ADHD--promising directions.Current psychiatry reports · 2014Review
- Advances in molecular genetic studies of attention deficit hyperactivity disorder in China.Shanghai archives of psychiatry · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atomoxetine, a selective inhibitor of the norepinephrine transporter, exerts its therapeutic effect for attention-deficit hyperactivity disorder (ADHD) by increasing the concentration of synaptic norepinephrine. The objective of this study was to evaluate the association of the genetic variants of multiple genes of the noradrenergic neurotransmitter system with atomoxetine response. One hundred and eleven ADHD children and adolescents were enrolled in a prospective, open-label study of atomoxetine for 8-12 weeks. The dose was titrated to 1.2-1.4 mg/kg per day and maintained for at least 4 weeks. The primary efficacy measure was the investigator-rated ADHD Rating Scale-IV. Two categorical evaluations of treatment effects (defined as response and remission) were used. Twelve SNPs in SLC6A2, ADRA2A, and ADRA1A were genotyped to analyze their association with response or remission status. rs3785143 in SLC6A2 was associated with responder status (nominal P = 0.0048; corrected by multiple test, P = 0.0416; OR 2.66, 95 % confidence interval (CI) 1.35-5.26). rs2279805 of SLC6A2 was nominally significantly associated with the remission status. (P = 0.0221, OR 2.32, 95 % CI 1.13-4.75, multiple test P = 0.2130). The GG haplotype of rs1800544 and rs553668 in ADRA2A achieved nominal significance for association with non-remission (P = 0.0219, OR 2.82, 95 % CI 1.16-6.85, multiple test, P = 0.2076). The results of this study suggest that DNA variants of both SLC6A2 and ADRA2A in the adrenergic neurotransmitter system might alter the response to atomoxetine, though further replication study in larger sample for validation of these findings is still needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.